We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 0.69% | 220.00 | 218.00 | 219.50 | 223.00 | 212.50 | 219.00 | 275,208 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.67 | 211.03M |
TIDMOXB
RNS Number : 1974O
Oxford Biomedica PLC
05 February 2021
TR-1 annoucement of major holdings
Oxford, UK - 5 February 2021: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Testudo/Lifesciences Fund, has advised the Group that on 4 February 2021 it sold 970,000 ordinary shares of 50p each in the Group. The shares have been acquired by a subsidiary of Vitruvian Investment Partnership III, a fund managed by Vitruvian Partners LLP. Vitruvian Partners is a leading global growth investment firm with EUR10bn AUM, and has supported some of Europe's most successful high growth innovators. They are highly respected with a long term focus and strong interest in cell and gene therapy.
Martin Diggle from VulpesTestudo/Lifesceinces Fund said: "Through the recent sale of a portion of our holding to Vitruvian Partners LLP, Oxford Biomedica gains another well respected long-term shareholder. We are excited about the future for the Group, remain fully supportive of the business and continue to retain a significant shareholding."
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) (i) 1a. Identity of the issuer or the OXFORD BIOMEDICA PLC underlying issuer of existing shares to which voting rights are attached (ii) : -------------------------------------------- 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer ---- 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X ---- An acquisition or disposal of financial instruments ---- An event changing the breakdown of voting rights ---- Other (please specify)(iii) : ---- 3. Details of person subject to the notification obligation (iv) Name VULPES LIFE SCIENCES FUND VULPES TESTUDO FUND City and country of registered office CAYMAN ISLANDS (if applicable) 4. Full name of shareholder(s) (if different from 3.) (v) Name -------------------------------------------- City and country of registered office (if applicable) -------------------------------------------- 5. Date on which the threshold was 04/02/2021 crossed or reached (vi) : -------------------------------------------- 6. Date on which issuer notified (DD/MM/YYYY): 05/02/2021 -------------------------------------------- 7. Total positions of person(s) subject to the notification obligation % of voting % of voting rights Total of both Total number rights attached through financial in % (8.A + of voting rights to shares (total instruments 8.B) of issuer (vii) of 8. A) (total of 8.B 1 + 8.B 2) ------------------ --------------------- -------------- -------------------- Resulting situation on the date on which threshold was crossed or reached 11.86% 0% 11.86% 9,768,615 ------------------ --------------------- -------------- -------------------- Position of previous notification (if applicable) - 0% ------------------ --------------------- -------------- -------------------- 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached (viii) A: Voting rights attached to shares Class/type Number of voting rights (ix) % of voting rights of shares ISIN code (if possible) Direct Indirect Direct Indirect (Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive 2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC) (DTR5.1) (DTR5.2.1) (DTR5.2.1) -------------------------- GB0006648157 9,768,615 11.86% ---------------------- -------------------------- ------------------------- --------------------- SUBTOTAL 8. A 9,768,615 11.86% -------------------------------------------------- ------------------------------------------------ B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of financial Expiration Exercise/ Number of voting % of voting rights instrument date Conversion Period rights that may (x) (xi) be acquired if the instrument is exercised/converted. ----------- ------------------------------ -------------------------------- --------------------- SUBTOTAL 8. B 1 ------------------------------ -------------------------------- --------------------- B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of Expiration Exercise/ Physical or Number of % of voting rights financial date (x) Conversion cash voting rights instrument Period (xi) settlement (xii) ---------------- -------------------- -------------------- -------------------- SUBTOTAL 8.B.2 -------------------- -------------------- 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled X by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer(xiii) Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(xiv) (please add additional rows as necessary) Name (xv) % of voting rights % of voting rights Total of both if if it equals or through financial it equals or is is higher than the instruments if it higher than the notifiable threshold equals or is higher notifiable threshold than the notifiable threshold ---------------------- --------------------- ------------------------ 10. In case of proxy voting, please identify: Name of the proxy holder ----------------------------------------------- The number and % of voting rights held ----------------------------------------------- The date until which the voting rights will be held ----------------------------------------------- 11. Additional information (xvi) Place of completion London, UK Date of completion 04 February 2021 ----------------- Contact name: Natalie Walter Contact telephone number: 01865 783000 ---------------
-Ends-
Enquiries: Oxford Biomedica plc John Dawson, Chief Executive Officer T: +44 (0)1865 783 000 Stuart Paynter, Chief Financial Officer T: +44 (0)1865 783 000 Catherine Isted, Head of Corporate T: +44 (0)1865 954 161 / E: ir@oxb.com Development & IR Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal T: +44 (0)20 3709 5700
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLEADASEAEFEFA
(END) Dow Jones Newswires
February 05, 2021 08:22 ET (13:22 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions